Compare Regeneron Pharmaceuticals Inc (REGN) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Western Union Co — how do they compare? Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B), while Western Union Co trades at $6.33 (market cap $1.91B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 40× Western Union Co's market cap, and Western Union Co pays the higher dividend (15.38%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Western Union Co for 95 Days on average.
| REGN | WU | |
|---|---|---|
Market Cap | $76.40B | $1.91B |
Volume | 626,381 | 6,459,194 |
Sector | Health | Financials |
52-Week High | $852.03 | $10.28 |
52-Week Low | $557.73 | $5.90 |
Typical Hold Time | 107 Days | 95 Days |
Enterprise Value | $71.12B | $1.81B |
Dividend Yield | 0.51% | 15.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Western Union (WU) trades at $6.33, up 3.09% with bearish technical signals but attractive valuation metrics including a P/E of 4.93 and P/S of 0.48. Recent earnings show mixed performance with two misses in the last three quarters, while the company maintains strong profitability with 9.79% net margin and 43.97% ROE. The $200 million Beyond Efficiency Plan and pending Intermex acquisition represent key strategic initiatives amid declining revenue trends from $4.5B in 2022 to $4.0B projected for 2026.
WU presents a value opportunity with deep valuation discounts but faces significant headwinds including revenue contraction and integration risks from the Intermex acquisition. Analyst sentiment remains cautious with only 12% buy ratings, though the $6.86 consensus target offers 8% upside. The stock's appeal hinges on successful cost-cutting execution and digital transformation amid competitive pressures in money transfer services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
